Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
About us
People
Jakob Ribbing

Jakob Ribbing

Jakob Ribbing, Ph.D.

Principal Director, MIDD Consultant & Senior Expert

Google scholar

Joined Pharmetheus in 2014, actively working in client and internal projects/roles, and serving as Client Operations Expert and Deputy Project Portfolio Team Leader
Expertise includes pharmacometrics, model-informed drug development, model based meta analysis, and pediatrics in therapeutic areas such as allergy, inflammation, respiratory, neuroscience, oncology and diabetes
Previously worked as Associate Director in Pharmacometrics at Pfizer in UK and Sweden, where he was responsible for team interaction and pharmacometrics deliveries for the Pfizer Allergy and Respiratory portfolio, as well as support to Pfizer global pharmacometrics and clinical pharmacology, and as Manager in Pharmacometrics at Pfizer INC, UK
M.Sc. in Pharmacy (2001) and Ph.D. in Biopharmaceutical Sciences (2007) from Uppsala University, Sweden

Pharmetheus affiliated publications

Population pharmacokinetics and pharmacodynamics of depemokimab in people with asthma and chronic rhinosinusitis with nasal polyps Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib Exposure-Efficacy Meta-model of Nintedanib in Adult Patients with Chronic Fibrosing Interstitial Lung Diseases Assessment of Phase 1 pharmacokinetic-pharmacodynamic predictions, based on Phase 3 clinical trials results. Depemokimab pharmacokinetics and response in blood eosinophil count reduction for asthma and chronic rhinosinusitis with nasal polyps patients Population pharmacokinetic analysis of doxecitine and doxribtimine in patients with thymidine kinase 2 deficiency and in healthy volunteers Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease Covariate modeling in pharmacometrics: General points for consideration Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis [2] Population Pharmacokinetic Analysis of Etrolizumab in Patients with Moderately-to-Severely Active Ulcerative Colitis Exposure-Response Analysis of Etrolizumab in Patients with Moderately-to-severely Active Ulcerative Colitis Translating Pharmacometrics to a Pharmacoeconomic Model of COPD Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1 – A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Science & Services
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Whistleblower
Privacy Policy
Cookie Policy